全文获取类型
收费全文 | 15315篇 |
免费 | 1050篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 127篇 |
儿科学 | 477篇 |
妇产科学 | 421篇 |
基础医学 | 1880篇 |
口腔科学 | 227篇 |
临床医学 | 2677篇 |
内科学 | 2781篇 |
皮肤病学 | 202篇 |
神经病学 | 1348篇 |
特种医学 | 362篇 |
外国民族医学 | 2篇 |
外科学 | 1492篇 |
综合类 | 260篇 |
一般理论 | 29篇 |
预防医学 | 1751篇 |
眼科学 | 307篇 |
药学 | 913篇 |
2篇 | |
中国医学 | 7篇 |
肿瘤学 | 1124篇 |
出版年
2023年 | 62篇 |
2022年 | 139篇 |
2021年 | 245篇 |
2020年 | 157篇 |
2019年 | 260篇 |
2018年 | 307篇 |
2017年 | 238篇 |
2016年 | 239篇 |
2015年 | 269篇 |
2014年 | 367篇 |
2013年 | 642篇 |
2012年 | 871篇 |
2011年 | 1024篇 |
2010年 | 551篇 |
2009年 | 539篇 |
2008年 | 942篇 |
2007年 | 973篇 |
2006年 | 1018篇 |
2005年 | 983篇 |
2004年 | 1026篇 |
2003年 | 962篇 |
2002年 | 869篇 |
2001年 | 243篇 |
2000年 | 184篇 |
1999年 | 206篇 |
1998年 | 189篇 |
1997年 | 157篇 |
1996年 | 121篇 |
1995年 | 126篇 |
1994年 | 93篇 |
1993年 | 89篇 |
1992年 | 177篇 |
1991年 | 119篇 |
1990年 | 144篇 |
1989年 | 116篇 |
1988年 | 111篇 |
1987年 | 126篇 |
1986年 | 118篇 |
1985年 | 114篇 |
1984年 | 105篇 |
1983年 | 116篇 |
1982年 | 76篇 |
1981年 | 78篇 |
1980年 | 97篇 |
1979年 | 69篇 |
1978年 | 72篇 |
1977年 | 70篇 |
1975年 | 58篇 |
1974年 | 54篇 |
1973年 | 53篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
13.
14.
15.
Donald B. Penzien PhD ; Frank Andrasik PhD ; Brian M. Freidenberg PhD ; Timothy T. Houle PhD ; Alvin E. Lake III PhD; Gay L. Lipchik PhD ; Kenneth A. Holroyd PhD ; Richard B. Lipton MD ; Douglas C. McCrory MD ; Justin M. Nash PhD ; Robert A. Nicholson PhD ; Scott W. Powers PhD ABPP ; Jeanetta C. Rains PhD ; David A. Wittrock PhD 《Headache》2005,45(S2):S110-S132
Guidelines for design of clinical trials evaluating behavioral headache treatments were developed to facilitate production of quality research evaluating behavioral therapies for management of primary headache disorders. These guidelines were produced by a Workgroup of headache researchers under auspices of the American Headache Society. The guidelines are complementary to and modeled after guidelines for pharmacological trials published by the International Headache Society, but they address methodologic considerations unique to behavioral and other nonpharmacological treatments. Explicit guidelines for evaluating behavioral headache therapies are needed as the optimal methodology for behavioral (and other nonpharmacologic) trials necessarily differs from the preferred methodology for drug trials. In addition, trials comparing and integrating drug and behavioral therapies present methodological challenges not addressed by guidelines for pharmacologic research. These guidelines address patient selection, trial design for behavioral treatments and for comparisons across multiple treatment modalities (eg, behavioral vs pharmacologic), evaluation of results, and research ethics. Although developed specifically for behavioral therapies, the guidelines may apply to the design of clinical trials evaluating many forms of nonpharmacologic therapies for headache. 相似文献
16.
17.
C Gay Escoda 《Avances en Odontoestomatología》1987,3(4):169-72, 175-9
18.
19.
G. Bradley Schaefer James N. Thompson John B. Bodensteiner James M. McConnell William J. Kimberling Charles T. Gay William D. Dutton David C. Hutchings Stanton B. Gray 《Annals of neurology》1996,39(3):382-385
There are conflicting reports on the relationship between cerebellar vermal lobule hypoplasia and autism. Using quantitative magnetic resonance image analysis, we measured the cerebellar vermis in 125 normal individuals with a broad age range and 102 patients with a variety of neurogenetic abnormalities. We conclude that hypoplasia of cerebellar vermal lobules VI and VII is a nonspecific finding that even occurs in several conditions without autistic behavior. This suggests that it is not a specific neuroanatomical marker for autism, nor is cerebellar dys- genesis likely to be solely responsible for clinical autistic behaviors. 相似文献
20.
J F Newton K M Straub R H Dewey C D Perchonock M E McCarthy J G Gleason R K Lynn 《Drug metabolism and disposition》1992,20(4):479-484
A primary route of inactivation of leukotrienes and their receptor antagonists (LTRA) is metabolism by omega oxidation. SK&F 102922 [5-(2-(8-phenyloctyl)phenyl)-4,6-dithianonanedioic acid] is a LTRA that was designed to be resistant to omega oxidation. Therefore, these experiments were designed to characterize the metabolic fate of [14C]SK&F 102922. Following iv administration of SK&F 102922 (5 mg/kg), 80% of injected radioactivity was excreted in bile in 1 hr. At least five metabolites and parent (18% of administered dose) were present in bile. One metabolite (M1), which accounted for less than 10% of the excreted radioactivity, was monohydroxylated. Three metabolites (M2, M3A, and M3B), which together accounted for greater than 50% of excreted radioactivity, had mass spectra consistent with acyl glucuronides. All three metabolites were alkali labile, whereas only one metabolite (M2) was susceptible to beta-glucuronidase hydrolysis. These data indicate that M3a and M3b are nonglycosidic isomers of M2 that were formed by a nonenzymic reaction involving migration of the aglycone (SK&F 102922) from C-1 to C-2, C-3, or C-4 of glucuronic acid. The 1-O-acyl-beta-glucuronide of SK&F 102922 (M2) exhibits pH dependent rearrangement, with half-lives ranging from 1 to greater than 1000 hr. Therefore, acyl glucuronidation can account for much of the metabolic fate of SK&F 102922 and, potentially, other structurally related LTRAs or endogenous leukotrienes themselves. 相似文献